newS & viewS 13%, P = 0.006), acute toxic effects (27% versus 40%, P = 0.001) and chronic toxic effects (14% versus 24%, P = 0.012). sphincter preservation in those patients judged by the surgeon to require an abdomino perineal resection was also improved with preoperative chemo radiotherapy (39% versus 19%; P = 0.005). with a median follow-up of 46 months, there was, however, no difference in 5-year DFs (68% versus 65%, P = 0.32) and overall survival (74% versus 76%, P = 0.8). thus, although both the nsaPB r-03 and Cao/aro/aio-94 trials support the role of preoperative versus postoperative chemoradiotherapy in locally advanced rectal cancer; these conclusions are based on different end points and the results from both studies were not always in agreement. there are a number of reasonable explanations for these different outcomes, including different chemo therapy regimens (induction chemotherapy was not used in the German trial) and surgical techniques: total mesorectal excision was mandatory in Cao/aro/aio-94. the most striking difference, however, is the fact that only 267 of 900 patients intended to be enrolled onto nsaBP r-03 were accrued, thereby limiting the statistical power to detect differences. For example, only 28 loco regional events were observed, and the statistical power to detect a 33% reduction in local recurrence was only 18%.
apart from the Cao/aro/aio-94 trial, the only other randomized (and completed) trial in patients with rectal cancer that has compared preoperative with post operative radiotherapy, both without chemo therapy, has been the uppsala trial, which was carried out between 1980 and 1985. 6 in the preoperative arm of this trial, patients received short-course radiotherapy (five fractions of 5.1 Gy), and patients in the postoperative arm received conventional radiotherapy (2 Gy to a total of 60 Gy with a 2-week break after 40 Gy). Preoperative radiotherapy signifi cantly decreased local failure rate (13% versus 22%, P = 0.02); however, there was no significant difference in 5-year overall survival (42% versus 38%). the swedish Council of technology assessment in Health Care performed a systematic review of radiotherapy trials for rectal cancer patients. 7 they analyzed data from 42 random ized trials, 3 meta-analyses, 36 prospective studies, 7 retro spective studies and 17 other articles, for a total of 25,351 patients. the main conclusion of this systematic review was that pre operative radiotherapy at bio logically effective doses above 30 Gy decreases the relative risk of local failure by 50−70%, and post operative radiotherapy (at doses that are usually higher than those used pre operatively) reduced the relative risk by 30−40%, and preoperative radiotherapy improved survival by about 10%.
the most recent medical research Council trial C07 randomly assigned 1,350 patients with clinical stage i-iii rectal cancer to preoperative radiotherapy (five fractions of 5 Gy) or selective postoperative chemo radiotherapy (45 Gy with 5-Fu), which was applied only in patients with a histologic circum ferential resection margin below 1 mm. results after a median follow-up of 4 years showed local recurrence rates at 3 years of 4.4% for patients treated preoperatively and 10.6% for patients treated by selective postoperative chemoradiotherapy (P <0.0001), and an absolute difference in DFs at 3 years of 6.0% (77.5% preoperatively versus 71.5% postoperatively, P = 0.013). 8 in conclusion, although nsaBP r-03 showed no improvement in local control, sphincter preservation, and acute toxic effects in the preoperative arm compared with the postoperative therapy arm, the finding of a significant improvement in DFs adds to the plethora of data that favor preoperative treatment compared with primary surgery for patients with locally advanced rectal cancer. Current clinical trials are continuing to investi gate the incorporation of moreeffective combination chemotherapy into the multi modality treatment of this disease. 1 spawned a host of post-hoc analyses of randomized trials and observational population-based studies to evaluate the relationship between aDt and cardiac morbidity and mortality. [2] [3] [4] [5] [6] to date, the evidence from these studies suggests that aDt modestly increases risk of cardiovascular disease but does not necessarily increase cardiovascular mortality. the absence of an apparent increase in cardiovascular mortality does not, however, exclude the possi bility of aDt increasing non-cancer mortality. Previous reports suggested higher noncancer mortality in men treated with longterm versus short-term adjuvant hormonal therapy for advanced disease 3 and decreased overall survival in those receiving neoadjuvant hormonal therapy before prostate brachytherapy for early-stage disease. attempted to evaluate the relationship between short-term aDt and all cause mortality (aCm) in men treated with brachytherapy for early-stage prostate cancer. this single institution, restro spective experience included 5,077 men with localized or locally advanced prostate cancer treated with or without a median of 4 months of neoadjuvant aDt followed by brachytherapy. aDt was linked to greater aCm (P = 0.04) after a median follow-up of 5.1 years in a small subgroup (n = 256) of men with coronary artery disease (CaD)-induced congestive heart failure (CHF) or prior myocardial infarction, but not among the majority of men without those conditions.
we commend the authors on their attempt to define a subgroup of patients in whom aDt is possibly dangerous, and agree that hormonal therapy is not suitable for everyone. Yet, caution must be exercised in the interpretation of the results of this study. First, because prostate cancer is an indolent disease, it is unclear why men with clinically significant cardiovascular disease were treated with brachytherapy rather than managed by active surveillance. second, there is no established survival benefit for aDt in combination with brachytherapy and it is unclear why so many men received aDt in this setting. third, there are concerns raised over ascertainment biases in that the main conclusion associating aDt with greater aCm in men with CaDinduced CHF or prior myocardial infarction is based on a small subset representing only 5% of the entire study population and a difference of only seven events. the choice of aCm as an end point is parti cularly surprising because the men who received aDt had more adverse features than patients who did not receive it, including older age, and more-aggressive cancers. unfortunately, the authors did not report cancer-specific or non-cancer mortality, so it remains unclear whether the link to greater aCm was related to prostate cancer, its treatment, or the selection of patients at greater risk for death.
notably, an analysis of a large, multicenter, prospective randomized controlled trial with long follow-up found that even within subgroups of men with high-risk of cardiac death (that is, age 70 years or older, prevalent cardio vascular disease or diabetes) there was no apparent increase in cardio vascular morta lity in those treated with adjuvant aDt for locally advanced prostate cancer. 2 similarly, analyses of another large randomized trial 4 have also reported no excess cardio vascular mortality in men receiving short-term aDt in combination with radiation therapy versus radiation alone.
Herein lies the true lesson of the nanda study. aDt as an adjunct to radiation was adopted in the 1990s for advanced disease on good evidence. in fact, it is firmly established that hormonal therapy decreases cancerspecific and, in some cases, aCm for men with locally advanced or high-grade localized prostate cancer. regrettably, this evidence of improved survival has, in part, led to the increase in the use of hormonal therapy across the entire spectrum of disease even among men with lower-risk prostate cancer and older men with significant competing causes of mortality.
9 this over-exuberant expansion in the indications for hormonal therapy might reflect both the optimism and good intentions of treating physicians; however, the issue of financial reimbursement could be involved as well. 10 the results of the radiation therapy oncology Group (rtoG) 94-08 study (presented as a late-breaking abstract at astro annual meeting 2009) are of paramount importance to informing proper patterns of practice. this landmark trial demonstrated that short-term aDt before and during radiation therapy modestly improved overall survival (P = 0.03) in patients with early-stage localized prostate cancer and notably did not increase the risk of intercurrent death. the actuarial 10-year death rate from intercurrent disease (excluding deaths from prostate cancer) was 35% in the aDt plus radiation therapy arm and 37% in the radiation alone arm (P = 0.49). the results of the risk group analysis revealed that the intermediate-risk subgroup experienced the greatest benefit from short-term aDt, although it is debatable whether this remains valid in the era of dose-escalated radiation therapy (which is being addressed in an ongoing rtoG trial). results of this risk group analysis, however, demonstrate that there is no role for hormone therapy in low-risk disease. secondary analyses from this important randomized trial will help shed further light on the unintended adverse effects of hormonal therapy in early stage disease, including those with significant cardiac co-morbidity.
we strongly recommend limiting use of adjunctive aDt to settings with an established survival benefit. these evidence-based indications include men receiving externalbeam radiation therapy for intermediate and high-risk disease. the absence of an established survival benefit should be sufficient reason to avoid aDt in other settings, including men receiving brachy therapy and/ or external-beam radiation therapy for lowrisk disease. the increased understanding of potential adverse effects of aDt serves to reinforce careful selection of appropriate candidates for treatment.
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Clinicians should not necessarily withhold aDt from men who might benefit from it in terms of cancer-specific survival despite a history of cardiac co-morbidity after careful consideration of the risks and benefits. Good general medical care dictates that patients with underlying cardiac disease receive secondary preventive measures, including lipid-lowering, anti hypertensive, glucose lowering, and antiplatelet therapy as appropriate. there is no evidence to recommend additional cardiac testing or coronary intervention in patients with cardiovascular disease before initiation of aDt. in lieu of a randomized controlled trial directly addressing the question of the effect of aDt on cardiac health, we believe that future trials of aDt as well as novel forms of hormone therapy should prospectively assess cardiovascular risk factors and stratify patients according to their co-morbidities.
the questions raised by the relationship between aDt and cardiac health in prostate cancer patients are complicated. the initial excitement surrounding hormonal therapy could now be over, as the relationship finds a new balance based on evidence. while therapeutic success using conventional doses of chemotherapy characterizes the management of childhood acute lymphoblastic leukemia (all), similar success has not been achieved in the manage ment of adult all. 1 as a consequence, the use of allogeneic hemato poietic stem-cell transplantation (HsCt) is not often used in the frontline management of childhood all; its use is largely restricted to patients with adverse blast cytogenetics such as t(9;22), t(4;11), or 11q23 mutations, patients with slow induction response or induction failure, and certain patients with very high white blood cell counts at diagnosis. 2 allogeneic HsCt is more commonly used in the management of adult all.
1 as treatment outcomes in young adult all patients where pediatric protocols have been used are superior to results achieved with adult all protocols, a question has arisen as to whether adult paradigms for use of HsCt should apply to young adult patients (that is patients aged 16-21 years) or whether a more-conservative management should be used for these patients.
efforts to answer questions regarding the outcomes of cancer treatment for young adults have been hampered by poor enrollment to clinical trials.
3,4 the cause of this is likely to be multifactorial, and includes adolescent concern with clinical trial participation and the transition from pediatric care to adult care which may be associated with decreased awareness of clinical trial availability. Despite these impediments, previous research has demonstrated superior outcomes for young adult all patients up to 30 years of age when treated following protocols designed by pediatric oncologists. [5] [6] [7] [8] owing to the disparities in treatment outcome for all noted in pediatric versus adult populations, nachman and colleagues 9 have focused their interest on the transitional group of all patients, aged 16-21 years. the young adults evaluated in the nachman manuscript comprised 12.7% of the total population treated on the CCG-1961 study for high-risk all. the parent CCG-1961 study enrolled 2,057 eligible patients, newly diagnosed and aged 1-21 years; those below 10 years of age had to have a white blood cell count >50,000/ul at diagnosis. Patients achieving a rapid early response (<25% blasts on day 7 bone marrow) were random ized in a 2 × 2 factorial design to one
